![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: YTHDF2 |
Gene summary for YTHDF2 |
![]() |
Gene information | Species | Human | Gene symbol | YTHDF2 | Gene ID | 51441 |
Gene name | YTH N6-methyladenosine RNA binding protein 2 | |
Gene Alias | CAHL | |
Cytomap | 1p35.3 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9Y5A9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51441 | YTHDF2 | LZE4T | Human | Esophagus | ESCC | 3.85e-15 | 2.06e-01 | 0.0811 |
51441 | YTHDF2 | LZE5T | Human | Esophagus | ESCC | 2.03e-03 | -1.11e-01 | 0.0514 |
51441 | YTHDF2 | LZE7T | Human | Esophagus | ESCC | 1.19e-12 | 1.04e+00 | 0.0667 |
51441 | YTHDF2 | LZE8T | Human | Esophagus | ESCC | 6.20e-06 | 2.75e-01 | 0.067 |
51441 | YTHDF2 | LZE20T | Human | Esophagus | ESCC | 6.14e-03 | 1.79e-01 | 0.0662 |
51441 | YTHDF2 | LZE22T | Human | Esophagus | ESCC | 1.40e-03 | 5.54e-01 | 0.068 |
51441 | YTHDF2 | LZE24T | Human | Esophagus | ESCC | 2.35e-16 | 6.82e-01 | 0.0596 |
51441 | YTHDF2 | LZE6T | Human | Esophagus | ESCC | 5.35e-04 | 2.61e-01 | 0.0845 |
51441 | YTHDF2 | P2T-E | Human | Esophagus | ESCC | 6.41e-48 | 1.26e+00 | 0.1177 |
51441 | YTHDF2 | P4T-E | Human | Esophagus | ESCC | 1.34e-27 | 7.27e-01 | 0.1323 |
51441 | YTHDF2 | P5T-E | Human | Esophagus | ESCC | 7.73e-19 | 5.21e-01 | 0.1327 |
51441 | YTHDF2 | P8T-E | Human | Esophagus | ESCC | 1.07e-21 | 6.12e-01 | 0.0889 |
51441 | YTHDF2 | P9T-E | Human | Esophagus | ESCC | 1.12e-16 | 2.65e-01 | 0.1131 |
51441 | YTHDF2 | P10T-E | Human | Esophagus | ESCC | 4.10e-45 | 1.21e+00 | 0.116 |
51441 | YTHDF2 | P11T-E | Human | Esophagus | ESCC | 1.61e-18 | 8.27e-01 | 0.1426 |
51441 | YTHDF2 | P12T-E | Human | Esophagus | ESCC | 3.74e-27 | 8.94e-01 | 0.1122 |
51441 | YTHDF2 | P15T-E | Human | Esophagus | ESCC | 5.89e-38 | 1.12e+00 | 0.1149 |
51441 | YTHDF2 | P16T-E | Human | Esophagus | ESCC | 3.34e-33 | 7.86e-01 | 0.1153 |
51441 | YTHDF2 | P17T-E | Human | Esophagus | ESCC | 7.79e-05 | 6.52e-01 | 0.1278 |
51441 | YTHDF2 | P19T-E | Human | Esophagus | ESCC | 2.57e-06 | 5.73e-01 | 0.1662 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
GO:0042254111 | Esophagus | ESCC | ribosome biogenesis | 252/8552 | 299/18723 | 3.27e-44 | 1.04e-40 | 252 |
GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
GO:0016072110 | Esophagus | ESCC | rRNA metabolic process | 197/8552 | 236/18723 | 1.31e-33 | 1.18e-30 | 197 |
GO:0006364110 | Esophagus | ESCC | rRNA processing | 189/8552 | 225/18723 | 4.88e-33 | 3.87e-30 | 189 |
GO:0002181111 | Esophagus | ESCC | cytoplasmic translation | 135/8552 | 148/18723 | 4.17e-32 | 2.65e-29 | 135 |
GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
GO:0009896111 | Esophagus | ESCC | positive regulation of catabolic process | 332/8552 | 492/18723 | 4.36e-23 | 9.22e-21 | 332 |
GO:0031331111 | Esophagus | ESCC | positive regulation of cellular catabolic process | 292/8552 | 427/18723 | 8.67e-22 | 1.53e-19 | 292 |
GO:1903311110 | Esophagus | ESCC | regulation of mRNA metabolic process | 210/8552 | 288/18723 | 3.25e-21 | 5.56e-19 | 210 |
GO:0006401110 | Esophagus | ESCC | RNA catabolic process | 204/8552 | 278/18723 | 3.39e-21 | 5.66e-19 | 204 |
GO:0006413110 | Esophagus | ESCC | translational initiation | 100/8552 | 118/18723 | 1.16e-18 | 1.25e-16 | 100 |
GO:0034655110 | Esophagus | ESCC | nucleobase-containing compound catabolic process | 272/8552 | 407/18723 | 2.92e-18 | 2.90e-16 | 272 |
GO:0006402110 | Esophagus | ESCC | mRNA catabolic process | 170/8552 | 232/18723 | 8.70e-18 | 8.00e-16 | 170 |
GO:0006417111 | Esophagus | ESCC | regulation of translation | 304/8552 | 468/18723 | 1.53e-17 | 1.33e-15 | 304 |
GO:004670018 | Esophagus | ESCC | heterocycle catabolic process | 286/8552 | 445/18723 | 1.12e-15 | 7.47e-14 | 286 |
GO:0045727111 | Esophagus | ESCC | positive regulation of translation | 107/8552 | 136/18723 | 2.79e-15 | 1.68e-13 | 107 |
GO:004427019 | Esophagus | ESCC | cellular nitrogen compound catabolic process | 288/8552 | 451/18723 | 3.03e-15 | 1.79e-13 | 288 |
GO:0034250111 | Esophagus | ESCC | positive regulation of cellular amide metabolic process | 123/8552 | 162/18723 | 3.32e-15 | 1.93e-13 | 123 |
GO:001943918 | Esophagus | ESCC | aromatic compound catabolic process | 295/8552 | 467/18723 | 1.09e-14 | 5.98e-13 | 295 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
YTHDF2 | insertion | Nonsense_Mutation | novel | c.551_552insATGACCTGTGCATGTAGAAACTTGTTTGA | p.Ile185Ter | p.I185* | Q9Y5A9 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
YTHDF2 | SNV | Missense_Mutation | rs528989825 | c.410A>G | p.Asn137Ser | p.N137S | Q9Y5A9 | protein_coding | tolerated(1) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
YTHDF2 | SNV | Missense_Mutation | novel | c.1608G>T | p.Lys536Asn | p.K536N | Q9Y5A9 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
YTHDF2 | SNV | Missense_Mutation | c.91N>A | p.Asp31Asn | p.D31N | Q9Y5A9 | protein_coding | tolerated(0.11) | possibly_damaging(0.578) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
YTHDF2 | SNV | Missense_Mutation | novel | c.188C>G | p.Ser63Cys | p.S63C | Q9Y5A9 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
YTHDF2 | insertion | Frame_Shift_Ins | novel | c.508_509insACGTCGCAGAA | p.Ala170AspfsTer17 | p.A170Dfs*17 | Q9Y5A9 | protein_coding | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD | ||
YTHDF2 | SNV | Missense_Mutation | c.1274G>A | p.Arg425His | p.R425H | Q9Y5A9 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
YTHDF2 | SNV | Missense_Mutation | c.850G>A | p.Val284Ile | p.V284I | Q9Y5A9 | protein_coding | tolerated(0.11) | benign(0.014) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
YTHDF2 | SNV | Missense_Mutation | c.1683N>T | p.Glu561Asp | p.E561D | Q9Y5A9 | protein_coding | deleterious(0) | probably_damaging(0.925) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
YTHDF2 | SNV | Missense_Mutation | rs775516240 | c.1408G>A | p.Val470Met | p.V470M | Q9Y5A9 | protein_coding | tolerated(0.47) | possibly_damaging(0.902) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |